CHINYERE OKEKE: Open Payments
NPI 1255562880 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 28 payments from 12 companies in 2025. Trend: 2023 $496 · 2024 $549 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $318 |
| Otsuka America Pharmaceutical, Inc. | 5 | $119 |
| Indivior Inc. | 3 | $86 |
| Intra-Sana Laboratories | 2 | $59 |
| Braeburn Inc. | 1 | $32 |
| Lilly USA, LLC | 1 | $29 |
| Amgen Inc. | 1 | $27 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
Products named: CAPLYTA, REXULTI, SUBLOCADE, RELTONE 200 MG, BRIXADI, MOUNJARO, OTEZLA, Kerendia.
Industry payments across NV — which companies pay providers there.
